IDSA关于产ESBL肠杆菌、耐碳青霉烯肠杆菌和难治性铜绿假单胞菌感染的治疗指南
美国感染病学会(IDSA)6名专家基于文献与临床经验,针对产超广谱β-内酰胺酶肠杆菌(ESBL-E)、耐碳青霉烯肠杆菌(CRE)和难治性铜绿假单胞菌(DTR-P. aeruginosa)感染制定治疗推荐。指南聚焦美国耐药流行病学,涵盖经验性治疗、疗程及目标治疗,适用于成人与儿童,截至2020年9月17日。
要点
- 针对ESBL-E、CRE和DTR-P. aeruginosa感染提供首选与替代治疗方案。
- 推荐基于病原体鉴定和药敏结果,兼顾成人与儿童。
- 指南聚焦美国耐药流行病学,将定期更新。
核心结论
- IDSA发布针对ESBL-E、CRE和DTR-P. aeruginosa感染的治疗指南,推荐基于文献和临床经验。
研究设计与样本
- 由6名感染病专家组成小组,基于文献回顾和临床经验制定推荐及理由。
主要发现
- 指南简要讨论经验性治疗选择、疗程及其他管理考虑。
- 大部分内容聚焦于已知病原体和药敏结果时的首选与替代治疗推荐。
- 治疗推荐适用于成人和儿童。
关键数值与推荐
- 指南截至2020年9月17日有效,将随新数据定期更新。
- 未来版本将扩展至其他革兰阴性耐药病原体。
临床怎么用
- 临床医生可参考指南选择ESBL-E、CRE和DTR-P. aeruginosa感染的目标治疗方案。
- 经验性治疗和疗程决策可结合指南中的简要讨论。
局限性
- 指南聚焦美国耐药流行病学和药物可及性,全球适用性有限。
- 指南截至2020年9月17日,后续新数据可能影响推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antimicrobial-resistant infections are commonly encountered in US hospitals and result in significant morbidity and mortality. This guidance document provides recommendations for the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). METHODS: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated common questions regarding the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Based on review of the published literature and clinical experience, the panel provide recommendations and associated rationale for each recommendation. Because of significant differences in the molecular epidemiology of resistance and the availability of specific anti-infective agents globally, this document focuses on treatment of antimicrobial-resistant infections in the United States. RESULTS: Approaches to empiric treatment selection, duration of therapy, and other management considerations are briefly discussed. The majority of guidance focuses on preferred and alternative treatment recommendations for antimicrobial-resistant infections, assuming that the causative organism has been identified and antibiotic susceptibility testing results are known. Treatment recommendations apply to both adults and children. CONCLUSIONS: The field of antimicrobial resistance is dynamic and rapidly evolving, and the treatment of antimicrobial-resistant infections will continue to challenge clinicians. This guidance document is current as of 17 September 2020. Updates to this guidance document will occur periodically as new data emerge. Furthermore, the panel will expand recommendations to include other problematic gram-negative pathogens in future versions. The most current version of the guidance including the date of publication can be found at www.idsociety.org/practice-guideline/amr-guidance/.
引用
- Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021. PMID: 33106864. doi:10.1093/cid/ciaa1478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。